CytomX Therapeutics (CTMX) reported a quarterly loss of $0.22 per share for the period ending December 2025, significantly worse than the Zacks Consensus Estimate of a loss of $0.08, marking an earnings surprise of -175.00%. This compares to a profit of $0.22 per share during the same quarter last year. Additionally, the company’s revenues totaled $0.66 million, falling short of estimates by 90.98% and down from $38.09 million year-over-year.
In the previous quarter, the company had anticipated a loss of $0.04 per share but ended up reporting a loss of $0.09, reflecting a -125% surprise. Over the last four quarters, CytomX has met consensus EPS estimates twice. For the upcoming quarter, the consensus EPS estimate stands at -$0.10, with projected revenues of $5.62 million.
Year-to-date, CytomX shares have risen approximately 9.9%, outperforming the S&P 500, which has declined by 3.1%. The Zacks Rank for CytomX is currently #3 (Hold), suggesting that shares are expected to perform in line with the market moving forward.
